Nuclear Factor kappa-light-chain enhancer of activated B cells (NF-kB)
|Product Family||Product Number||Product Description||Technical Manual|
|IB09001-32||Human NF-kB Reporter Assay System, 3 x 32 assays in 96-well format||Technical Manual|
|IB09001||Human NF-kB Reporter Assay System, 1 x 96-well format assays||Technical Manual|
|IB09002||Human NF-kB Reporter Assay System, 1 x 384-well format assays|
Kits are offered in different assay formats to accommodate researchers’ needs: 3x 32, 1x 96, and 1x 384 assay formats for screening small numbers of test compounds, as well as custom bulk reagents for HTS applications.
INDIGO’s Human NF-kB Assay kit is an all-inclusive, single use assay system. In addition to NF-kB Reporter Cells, kits provide optimized media for use during cell culture and in diluting user’s test samples, a positive control activator, Luciferase Detection Reagent, and a cell culture-ready assay plate. Reporter Cells are single use reagents. They can not be refrozen or maintained in extended culture.
Bulk assay reagents can be custom manufactured to accommodate any scale of HTS. Please inquire.
This assay system utilizes HEK293t cells that express NF-kB (nuclear factor kappa-light-chain enhancer of activated B Cells), and contain the luciferase reporter gene functionally linked to upstream NF-kB genetic response elements. Thus, quantifying changes in luciferase expression provides a sensitive surrogate measure of changes in the level of NF-kB activation.
NF-kB is a signal transduction dependent transcription factor. This NF-kB reporter cell line is validated to provide a robust dose-dependent activation response when treated with TNFa, or the Protein Kinase C activator Phorbol 12-myristate 13-acetate (PMA). As such, the principle application of this assay system is in the screening of test samples to quantify any functional activities that they may exert to modulate, either induce or suppress, NF-kB activities.
Service Assays: Human
The primary application of INDIGO’s cell-based nuclear receptor assays are to quantitatively assess the bioactivity of a test compound as an agonist (activator) or antagonist (inhibition of an agonist response) of a given receptor. Service assays include a positive control reference compound and ‘vehicle’ control for every experiment. A formal study report and all data files are provided to the client upon completion of the study. To receive a quote for your proposed study, complete & submit the online Request a Quote form or contact an INDIGO Customer Service Representative to discuss your desired study parameters.
Rifamycin SV exhibits strong anti-inflammatory in vitro activity through pregnane X receptor stimulation and NFkB inhibition
ABSTRACTRifamycin SV (rifamycin), is a member of the ansamycin family of antimicrobial compounds which kills bacteria commonly associated with infectious diarrhea and other enteric infections. Rifamycin has been found to be effective in experimental animal models of gut inflammation and its efficacy in these settings has been attributed partially to immunomodulatory non-bactericidal activities. This study
New Assay Critical to the Study of the Human Immune Responses and Cancers State College, PA (October 16, 2014) – INDIGO Biosciences, a leading provider of nuclear receptor products and services announced today that it has released a new nuclear factor kappa-light-chain enhancer of activated B cells (NF-κB) assay system. Three different assay kit formats